Ginkgo Bioworks (DNA) Projected to Release Earnings on Thursday

Ginkgo Bioworks (NYSE:DNA) is expected to announce its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Ginkgo Bioworks to announce earnings of ($0.8950) per share and revenue of $24.05 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Ginkgo Bioworks (NYSE:DNA) last issued its earnings results on Thursday, May 7th. The company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.21) by ($0.18). Ginkgo Bioworks had a negative net margin of 215.41% and a negative return on equity of 56.08%. The firm had revenue of $19.00 million during the quarter, compared to analysts’ expectations of $42.93 million.

Ginkgo Bioworks Stock Performance

DNA traded up $0.32 during trading on Tuesday, reaching $9.26. The company’s stock had a trading volume of 257,185 shares, compared to its average volume of 1,153,405. The company’s fifty day moving average price is $8.80 and its 200-day moving average price is $8.34. Ginkgo Bioworks has a 52-week low of $5.37 and a 52-week high of $17.58. The company has a market capitalization of $604.67 million, a price-to-earnings ratio of -1.74 and a beta of 1.78.

Wall Street Analyst Weigh In

DNA has been the subject of several research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ginkgo Bioworks in a research report on Friday, July 17th. Wall Street Zen downgraded shares of Ginkgo Bioworks from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. One research analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Reduce” and a consensus price target of $8.50.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Raymond James Financial Inc. acquired a new stake in Ginkgo Bioworks during the 2nd quarter valued at $29,000. Quarry LP acquired a new stake in shares of Ginkgo Bioworks during the third quarter valued at $29,000. Daiwa Securities Group Inc. purchased a new stake in Ginkgo Bioworks during the 2nd quarter worth about $71,000. Atom Investors LP acquired a new position in Ginkgo Bioworks in the 4th quarter valued at about $105,000. Finally, Acadian Asset Management LLC purchased a new position in Ginkgo Bioworks in the 1st quarter valued at about $120,000. 78.63% of the stock is currently owned by institutional investors and hedge funds.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks, Inc is a synthetic biology company that designs custom microbes for customers across a range of industries. Utilizing a proprietary organism foundry platform, the company engineers cells to produce high-value chemicals, enzymes, and other biological materials. By integrating automation, data analytics and machine learning, Ginkgo Bioworks seeks to accelerate the development of biologically derived solutions at industrial scale.

The company’s services span the entire development cycle, from genetic design and strain optimization to fermentation and downstream processing.